GERMANTOWN, Maryland, and HILDEN, Germany, March 10, 2011
/PRNewswire-FirstCall/ --
- Vera Kallmeyer, M.D., Ph.D., and Elizabeth E. Tallett Nominated for
Election to the Supervisory Board at Next Annual General Meeting in June 2011
- Candidates Provide Extensive International Experience in the Health
Care Industry
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced today the
proposal of two international leaders in life sciences and healthcare - Dr.
Vera Kallmeyer, M.D., Ph.D., and Elizabeth E. Tallett - for election to its
Supervisory Board.
The Supervisory Board will propose these two independent candidates based
on their extensive experience in the life sciences and healthcare industries
as well as their roles as directors and officers in various international
companies.
Shareholders will vote on these and other proposals at the next Annual
General Meeting scheduled for June 30, 2011, including the reappointment of
all six current Supervisory Board members to one-year terms.
"We are very pleased to propose these two new highly skilled
international executives for election to our Board," said Prof. Dr. Detlev H.
Riesner, Chairman of the Supervisory Board and co-founder of QIAGEN N.V., and
Chairman of the Selection and Appointment Committee. "Their perspectives,
international experience in healthcare and academic research as well as their
diverse business backgrounds will be valuable resources to QIAGEN as we
expand our leading position in sample and assay technologies and their use in
research, applied markets and clinical diagnostics."
Dr. Vera Kallmeyer, M.D., Ph.D., is a Consulting Professor in the
Department of Neurosurgery at Stanford School of Medicine, where she teaches
courses in biomedical innovation, translational medicine and
entrepreneurship. She is the founder and managing partner of Equity4Health
LLC, a financial advisory and investment firm. She was formerly chief
financial officer and vice president of corporate development at Aviron Inc.
(now Medimmune/AstraZeneca), where she led several successful financing
rounds including the company's initial public offering which helped fuel
Aviron's substantial growth. She also held positions in investment banking
with Wasserstein Perella & Company and Flemings as well served in several
roles in training and practice in neurosurgery and cardiology. Dr. Kallmeyer
currently serves on the board of Elekta AB as well as the board of visitors
of UC Davis Medical School. Dr. Kallmeyer holds degrees from the Friedrich
Alexander University in Erlangen, Germany. She also attended Harvard Medical
School and the Royal Postgraduate School in London, and received an MBA and a
Certificate in Public Management from the Stanford Graduate School of
Business.
Elizabeth E. Tallett is a respected leader with more than 30 years of
experience in the pharmaceutical and biotechnology as well as broader
healthcare and financial industries. Her senior management experience
includes President and CEO of Transcell Technologies Inc., President of
Centocor Pharmaceuticals, member of the Parke-Davis Executive Committee, and
Director of Worldwide Strategic Planning for Warner-Lambert Company. Born and
educated in England, she graduated from Nottingham University with dual first
class honours degrees in mathematics and economics. Ms. Tallett is currently
a Principal of Hunter Partners, LLC, a management company for early to
mid-stage pharmaceutical, biotech and medical device companies. She is a
member of the board of directors of Principal Financial Group, Inc., Coventry
Health Care, Inc., Meredith Corp. and IntegraMed America, Inc. She is
currently the Lead Director for both Principal and Coventry Health Care. Ms.
Tallett was a founding board member of the Biotechnology Council of New
Jersey, and is a Trustee of Solebury School in Pennsylvania.
About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading global
provider of sample and assay technologies. Sample technologies are used to
isolate and process DNA, RNA and proteins from biological samples such as
blood or tissue. Assay technologies are used to make such isolated
bio-molecules visible. QIAGEN has developed and markets more than 500 sample
and assay products as well as automated solutions for such consumables. The
company provides its products to molecular diagnostics laboratories, academic
researchers, pharmaceutical and biotechnology companies, and applied testing
customers for purposes such as forensics, animal or food testing and
pharmaceutical process control. QIAGEN's assay technologies include one of
the broadest panels of molecular diagnostic tests available worldwide. This
panel includes the digene HPV Test, which is regarded as a "gold standard" in
testing for high-risk types of human papillomavirus (HPV), the primary cause
of cervical cancer, as well as a broad suite of solutions for infectious
disease testing and companion diagnostics. QIAGEN employs nearly 3,600 people
in over 30 locations worldwide. Further information about QIAGEN can be found
at http://www.qiagen.com/.
Certain of the statements contained in this news release may be
considered forward-looking statements within the meaning of Section 27A of
the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.
Securities Exchange Act of 1934, as amended. To the extent that any of the
statements contained herein relating to QIAGEN's products, markets, strategy
or operating results are forward-looking, such statements are based on
current expectations that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks associated
with management of growth and international operations (including the effects
of currency fluctuations and risks of dependency on logistics), variability
of operating results, the commercial development of the applied testing
markets, clinical research markets and proteomics markets, nucleic acid-based
molecular diagnostics market, and genetic vaccination and gene therapy
markets, competition, rapid or unexpected changes in technologies,
fluctuations in demand for QIAGEN's, products (including fluctuations due to
the level and timing of customers' funding, budgets, and other factors), our
ability to obtain regulatory approval of our infectious disease panels,
difficulties in successfully adapting QIAGEN's products to integrated
solutions and producing such products, the ability of QIAGEN to identify and
develop new products and to differentiate its products from competitors'
products, market acceptance of QIAGEN's new products and the integration of
acquired technologies and businesses. For further information, refer to the
discussions in reports that QIAGEN has filed with, or furnished to, the U.S.
Securities and Exchange Commission (SEC).
Contacts:
Investor Relations
Dr. Solveigh Mahler
+49-2103-29-11710
Albert F. Fleury
+1 301-944-7028
e-mail: ir@qiagen.com
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@qiagen.com
SOURCE QIAGEN N.V.
QIAGEN NV 
By 
